Anthony R. Mato

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 36 papers. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

3.5DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Leukemia(2020)10.1038/s41375-020-01030-2

N/A

0.705DataRank · unranked

109 citations

David A. Knorr, Melissa S. Pessin, Lakshmi V. Ramanathan, Meghan C. Thompson, Lori A. Leslie +3 more

DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study

American Journal of Hematology(2023)10.1002/ajh.26888

N/A

0.470DataRank · unranked

22 citations

Stephen J. Schuster, Wei Ding, Amber B. Koehler, Danielle M. Brander, Allison Rosenthal +10 more

Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology(2022)10.1016/j.critrevonc.2022.103696

N/A

0.449DataRank · unranked

19 citations

Tyler M. Andriano, Arpita Bose, Marina Chilov, Kendra Godwin, George Dranitsaris +6 more

Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1885664

N/A

0.425DataRank · unranked

16 citations

Varun Narendra, Justin Jee, Andriy Derkach, Molly Maloy, Mark B. Geyer +7 more

Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1221

N/A

0.385DataRank · unranked

12 citations

Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali +12 more

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Blood Advances(2024)10.1182/bloodadvances.2023011569

N/A

0.373DataRank · unranked

11 citations

Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen E. Spurgeon, Deborah M. Stephens +30 more

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Blood Advances(2025)10.1182/bloodadvances.2024013474

N/A

0.292DataRank · unranked

6 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +16 more

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Journal of Molecular Diagnostics(2023)10.1016/j.jmoldx.2023.02.005

N/A

0.241DataRank · unranked

4 citations

Mustafa Syed, Wayne Yu, Kasey R. Hutt, Alyssa M. Zlotnicki, Ying Huang +24 more

Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient

Cell Death & Disease(2025)10.1038/s41419-025-07884-7

N/A

0.208DataRank · unranked

3 citations

Paschalis Athanasiadis, Yanping Yin, Anne-Sofie F. Rise, Alberto J. Arribas, Luciano Cascione +8 more

BTK Inhibitors Versus Venetoclax as First‐ or Second‐Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real‐World Evidence Study

American Journal of Hematology(2025)10.1002/ajh.27639

N/A

0.165DataRank · unranked

2 citations

Yi Han, Anna Teschemaker, Anthony R. Mato, Meghan C. Thompson, Lindsey E. Roeker

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter’s transformation

Blood Advances(2021)10.1182/bloodadvances.2020003726

N/A

0DataRank · unranked

30 citations

Sean M. Devlin, Molly Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce +13 more

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1427

N/A

0DataRank · unranked

50 citations

Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato +1 more

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps7567

N/A

0DataRank · unranked

3 citations

Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch +9 more

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood Advances(2020)10.1182/bloodadvances.2020001956

N/A

0DataRank · unranked

86 citations

Peter Dreger, Jennifer R. Brown, Oscar Lahoud, Toby A. Eyre, Danielle M. Brander +20 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0964

N/A

0DataRank · unranked

13 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

0DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2148218

N/A

0DataRank · unranked

4 citations

Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, José F. Leis +7 more

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.04.14.488428

N/A

0DataRank · unranked

1 citations

Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Ishwarya Murali, Stacey M. Fernandes +11 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing

medRxiv(2022)10.1101/2022.10.03.22280675

N/A

0DataRank · unranked

1 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Nature Communications(2023)10.1038/s41467-023-42585-9

N/A

0DataRank · unranked

29 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

(2023)10.1158/1078-0432.c.6532718

N/A

0DataRank · unranked

0 citations

Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali +12 more

Data from Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

(2023)10.1158/1078-0432.c.6532596.v1

N/A

0DataRank · unranked

0 citations

Tatyana Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey +21 more

Data from Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

(2023)10.1158/1078-0432.c.6532718.v1

N/A

0DataRank · unranked

0 citations

Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali +12 more

Data from Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice

(2023)10.1158/2326-6066.c.6548944.v1

N/A

0DataRank · unranked

0 citations

Shiun Chang, Ayumi Hashimoto, Yi–Ju Chen, Chang Won Kang, Anthony R. Mato +4 more

Data from Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice

(2023)10.1158/2326-6066.c.6548944

N/A

0DataRank · unranked

0 citations

Shiun Chang, Ayumi Hashimoto, Yi–Ju Chen, Chang Won Kang, Anthony R. Mato +4 more

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science(2024)10.1126/science.adi5798

N/A

0DataRank · unranked

152 citations

Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C. Thompson, Alexandra Chirino +48 more

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

Clinical Lymphoma Myeloma & Leukemia(2020)10.1016/j.clml.2020.02.001

N/A

0DataRank · unranked

27 citations

Vincent A. LoRe, Anthony R. Mato, Elise A. Chong, Jacqueline C. Barrientos, James N. Gerson +7 more

Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1330

N/A

0DataRank · unranked

123 citations

Akihide Yoshimi, Jiguang Wang, Hana Cho, Stanley Chun-Wei Lee, Michelle Ki +11 more

COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia

Leukemia(2021)10.1038/s41375-021-01270-w

N/A

0DataRank · unranked

156 citations

David A. Knorr, Meghan C. Thompson, Mariely Nivar, Sonia Lebowitz, Nicole V. Peters +13 more

Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies

Blood Cancer Discovery(2021)10.1158/2643-3230.bcd-21-0139

N/A

0DataRank · unranked

75 citations

Gunjan L. Shah, Sean M. Devlin, Lakshmi Ramanathan, Sital Doddi, Melissa S. Pessin +19 more

Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts

American Journal of Hematology(2020)10.1002/ajh.25851

N/A

0DataRank · unranked

21 citations

Anthony R. Mato, John C. Byrd, Alexey V. Danilov, Brad Hedrick, Chaitra S. Ujjani +6 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more